Kunz-Schughart Leoni A, Freyer James P, Hofstaedter Ferdinand, Ebner Reinhard
Institute of Pathology, University of Regensburg, Franz-Josef-Strauss Allee 11, D-93042 Regensburg, Germany.
J Biomol Screen. 2004 Jun;9(4):273-85. doi: 10.1177/1087057104265040.
Over the past few years, establishment and adaptation of cell-based assays for drug development and testing has become an important topic in high-throughput screening (HTS). Most new assays are designed to rapidly detect specific cellular effects reflecting action at various targets. However, although more complex than cell-free biochemical test systems, HTS assays using monolayer or suspension cultures still reflect a highly artificial cellular environment and may thus have limited predictive value for the clinical efficacy of a compound. Today's strategies for drug discovery and development, be they hypothesis free or mechanism based, require facile, HTS-amenable test systems that mimic the human tissue environment with increasing accuracy in order to optimize preclinical and preanimal selection of the most active molecules from a large pool of potential effectors, for example, against solid tumors. Indeed, it is recognized that 3-dimensional cell culture systems better reflect the in vivo behavior of most cell types. However, these 3-D test systems have not yet been incorporated into mainstream drug development operations. This article addresses the relevance and potential of 3-D in vitro systems for drug development, with a focus on screening for novel antitumor drugs. Examples of 3-D cell models used in cancer research are given, and the advantages and limitations of these systems of intermediate complexity are discussed in comparison with both 2-D culture and in vivo models. The most commonly used 3-D cell culture systems, multicellular spheroids, are emphasized due to their advantages and potential for rapid development as HTS systems. Thus, multicellular tumor spheroids are an ideal basis for the next step in creating HTS assays, which are predictive of in vivo antitumor efficacy.
在过去几年中,建立和应用基于细胞的检测方法用于药物开发和测试已成为高通量筛选(HTS)中的一个重要课题。大多数新的检测方法旨在快速检测反映在各种靶点上作用的特定细胞效应。然而,尽管使用单层或悬浮培养的HTS检测方法比无细胞生化检测系统更复杂,但它们仍然反映了高度人工化的细胞环境,因此对于化合物的临床疗效可能具有有限的预测价值。当今的药物发现和开发策略,无论是基于假设还是基于机制的,都需要简便的、适用于HTS的检测系统,这些系统能够越来越准确地模拟人体组织环境,以便从大量潜在效应物中优化临床前和动物实验前对最具活性分子的选择,例如针对实体瘤的分子。事实上,人们认识到三维细胞培养系统能更好地反映大多数细胞类型的体内行为。然而,这些三维检测系统尚未纳入主流药物开发操作中。本文探讨了三维体外系统在药物开发中的相关性和潜力,重点是新型抗肿瘤药物的筛选。给出了癌症研究中使用的三维细胞模型的例子,并将这些中等复杂性系统的优点和局限性与二维培养和体内模型进行了比较。由于其优点以及作为HTS系统快速发展的潜力,最常用的三维细胞培养系统——多细胞球体受到了强调。因此,多细胞肿瘤球体是创建预测体内抗肿瘤疗效的HTS检测方法下一步的理想基础。